Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1) is a critical serine/threonine phosphatase that serves as a major negative regulator of the PI3K/Akt signaling pathway (UniProt O60346). By specifically dephosphorylating the hydrophobic motif of Akt at Ser-473, PHLPP1 terminates Akt activity, thereby promoting apoptosis and inhibiting cell proliferation (PubMed: 17350576). Beyond Akt, PHLPP1 also regulates other AGC kinases such as Protein Kinase C (PKC) and S6K1, and it plays a role in modulating the pro-apoptotic kinase Mst1 (PubMed: 21333914). In the context of oncology, PHLPP1 is frequently characterized as a tumor suppressor, and its expression is often lost or downregulated in various malignancies, including prostate, colon, and breast cancers (PubMed: 18042445). While there are currently no FDA-approved drugs targeting PHLPP1, small molecule inhibitors like NSC 117079 are utilized in research to explore its potential as a therapeutic target for neuroprotection and regenerative medicine (PubMed: 23839033). Its diverse roles in metabolism and circadian rhythms suggest that therapeutic modulation of PHLPP1 requires careful consideration of systemic safety profiles.
Dephosphorylation of the hydrophobic motif (Ser-473) of Akt, leading to its inactivation and the subsequent suppression of the PI3K/Akt signaling pathway (PubMed: 17350576). It also dephosphorylates and inactivates Protein Kinase C (PKC) and dephosphorylates the pro-apoptotic kinase Mst1 (PubMed: 21333914).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1) (PHLPP1).